Rani Therapeutics/RANI

$3.69

-1.33%
-
1D1W1MYTD1YMAX

About Rani Therapeutics

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company. The Company is focused on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The Company has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which is designed to deliver a variety of drug substances, including large molecules, such as peptides, proteins, and antibodies. The RaniPill capsule, the RaniPill GO, is designed to deliver up to a three micrograms (mg) dose of drug with high bioavailability. The capsule includes a coating designed to withstand stomach acid but dissolve in the jejunum portion of the small intestine. Its pipeline includes RT-101, RT-102, RT-105, RT-110 and RT-111. Its RT-101 is an Octreotide for the treatment of NETs and acromegaly. It manufactures and assembles RaniPill capsules at its facility in San Jose, California.

Ticker

RANI

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Mir Imran

Employees

163

Headquarters

San jose, United States

RANI Metrics

BasicAdvanced
$186.99M
Market cap
-
P/E ratio
-$1.41
EPS
-
Beta
-
Dividend rate

What the Analysts think about RANI

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 8 analysts.
221.95% upside
High $21.00
Low $4.00
$3.69
Current price
$11.88
Average price target

RANI Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-9.1M
-2.15%
Profit margin
0%
-

RANI Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 1.55%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.35
-$0.33
-$0.37
-$0.36
-
Expected
-$0.35
-$0.41
-$0.40
-$0.37
-$0.32
Surprise
0.57%
-20.19%
-8.48%
-1.55%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Rani Therapeutics stock

Buy or sell Rani Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing